May 30, 2019   SOURCE: PR NewsWire

Global Tumor-Specific Antigen Market Report 2019: 2017-2018 Data & CAGR Projections Through 2023

DUBLIN, May 30, 2019 /PRNewswire/ -- The "Global Tumor-Specific Antigen Market" report has been added to ResearchAndMarkets.com's offering.

https://mma.prnewswire.com/media/539438/Research_and_Markets_Logo.jpg

The scope of this report is broad and covers category, source and applications of Tumor-specific Antigen. The market has been segmented by source into coding region and Non-Coding region. Revenue forecasts from 2017 to 2023 are given for each segment and regional market with estimated value derived from the revenue of manufacturers.

The report also includes a discussion of the major players across each region of the Tumor-specific antigen market. Further, it explains the major drivers and regional dynamics of the global Tumor-specific antigen market and current trends within the industry.

The report concludes with a special focus on vendor landscape and includes detailed profiles of the main vendors in the Tumor-specific antigen market.

The Report Includes:

    --  An overview of the global market for tumor-specific antigen
    --  Analyses of global market trends, with data from 2017, 2018, and
        projections of compound annual growth rates (CAGRs) through 2023
    --  Coverage of various types of product available in the tumor-specific
        antigen market and discussion of their potential applications
    --  Information on oncofetal, oncoviral, overexpressed/accumulated, mutated,
        lineage restricted and idiotypic tumor-specific antigens and discussion
        of their specific targets
    --  Insights into regulatory framework and policies and funding initiatives
        by the government for cancer research
    --  A look into advancements in antigen specific T-Cell therapy for cancer
        and innovation within the industry
    --  Detailed profiles of the major vendors in the global tumor-specific
        antigen market including Agilent Technologies Inc., AIVITA Biomedical,
        Eli Lilly and Co., GO Therapeutics and Merck Millipore

Key Topics Covered:

Chapter 1 Introduction

    --  Study Goals and Objectives
    --  Reasons for Doing This Study
    --  Scope of Report
    --  Information Sources
    --  Methodology
    --  Geographic Breakdown
    --  Analyst's Credentials
    --  Custom Research
    --  Related Reports

Chapter 2 Summary and Highlights

Chapter 3 Market and Technology Background

    --  Market Overview
    --  Market Potential
    --  Investment Analysis
    --  Regulatory Framework
    --  United States
    --  European Union
    --  Australia
    --  Japan
    --  India
    --  China
    --  Industry Growth Drivers
    --  Surging Demand for Potential Cancer Biomarker Candidates
    --  Rising Prevalence of Cancer
    --  Increasing Investments in Cancer Diagnosis and Research
    --  Rising Focus on Developing Targeted Therapies
    --  Antigen Specific T-Cell Therapy

Chapter 4 Tumor-specific Antigen Market by Category

    --  Oncofetal
    --  Oncoviral
    --  Overexpressed/Accumulated
    --  CT9/CT10
    --  Mutated
    --  Lineage-Restricted Antigen
    --  Idiotypic
    --  Others

Chapter 5 Tumor-specific Antigen Market by Source

    --  Coding Region
    --  Non-Coding Region
    --  Growing the Background of Immunotherapy Targets

Chapter 6 Tumor-specific Antigen Market by Application

    --  Diagnostics
    --  Drug Discovery and Development
    --  Therapeutics
    --  Risk Assessment
    --  Prognostics
    --  Clinical and Basic Research

Chapter 7 Tumor-specific Antigen Market by Region

    --  North America
    --  United States
    --  Canada
    --  Europe
    --  United Kingdom
    --  France
    --  Germany
    --  Spain
    --  Rest of Europe
    --  Asia-Pacific
    --  China
    --  India
    --  Japan
    --  Australia
    --  Rest of Asia-Pacific
    --  Rest of the World
    --  Latin America
    --  Middle East and Africa

Chapter 8 Tumor-specific Antigen Market Industry Structure

    --  Industry Structure
    --  Procurement of Raw Materials
    --  Manufacturing/Development Process
    --  End-Users
    --  Innovation in the Market
    --  Competitive Analysis

Chapter 9 Company Profiles

    --  Abcam Plc
    --  Agilent Technologies Inc.
    --  Aivita Biomedical
    --  Bbi Group
    --  Bio-Rad Laboratories Inc.
    --  Biomrieux Sa
    --  Brightpath Biotherapeutics
    --  Caris Life Sciences Inc.
    --  Cisbio Bioassays
    --  Creative Diagnostics
    --  Eli Lilly And Co.
    --  Enzo Biochem Inc.
    --  Externautics
    --  F. Hoffmann-La Roche Ltd.
    --  Go Therapeutics
    --  Janssen Global Services Llc
    --  Lee Biosolutions Inc.
    --  Merck Millipore
    --  Meso Scale Diagnostics, Llc
    --  Perkinelmer Inc.
    --  Quest Diagnostics
    --  Signosis Inc.

For more information about this report visit https://www.researchandmarkets.com/r/m2vl5b

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Laura Wood, Senior Manager
press@researchandmarkets.com

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:http://www.prnewswire.com/news-releases/global-tumor-specific-antigen-market-report-2019-2017-2018-data--cagr-projections-through-2023-300858420.html

SOURCE Research and Markets